- Home
- GIGM vs SNTI Comparison
GIGM vs SNTI Comparison
Compare GIGM & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- SNTI
- Stock Information
- Founded
- GIGM 1998
- SNTI 2016
- Country
- GIGM Taiwan
- SNTI United States
- Employees
- GIGM N/A
- SNTI N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- SNTI Health Care
- Exchange
- GIGM Nasdaq
- SNTI Nasdaq
- Market Cap
- GIGM 17.0M
- SNTI 39.6M
- IPO Year
- GIGM 2000
- SNTI N/A
- Fundamental
- Price
- GIGM $1.81
- SNTI $1.37
- Analyst Decision
- GIGM
- SNTI Strong Buy
- Analyst Count
- GIGM 0
- SNTI 2
- Target Price
- GIGM N/A
- SNTI $8.50
- AVG Volume (30 Days)
- GIGM 22.4K
- SNTI 120.0K
- Earning Date
- GIGM 10-29-2025
- SNTI 11-13-2025
- Dividend Yield
- GIGM N/A
- SNTI N/A
- EPS Growth
- GIGM N/A
- SNTI N/A
- EPS
- GIGM N/A
- SNTI N/A
- Revenue
- GIGM $3,250,000.00
- SNTI N/A
- Revenue This Year
- GIGM N/A
- SNTI N/A
- Revenue Next Year
- GIGM N/A
- SNTI $150.00
- P/E Ratio
- GIGM N/A
- SNTI N/A
- Revenue Growth
- GIGM N/A
- SNTI N/A
- 52 Week Low
- GIGM $1.30
- SNTI $1.26
- 52 Week High
- GIGM $1.89
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- GIGM 66.43
- SNTI 37.01
- Support Level
- GIGM $1.61
- SNTI $1.33
- Resistance Level
- GIGM $1.89
- SNTI $1.39
- Average True Range (ATR)
- GIGM 0.09
- SNTI 0.08
- MACD
- GIGM 0.02
- SNTI 0.01
- Stochastic Oscillator
- GIGM 80.05
- SNTI 31.43
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.